Hyperrho

Product Specs	Description
Manufacturer Name	Grifols
Indications	Mini-Dose For prevention of isoimmunization in Rho(D) negative women at the time of spontaneous or induced abortion of up to 12 weeks’ gestation. Full Dose For prevention of Rh hemolytic disease of the newborn by its administration to the Rho(D) negative mother within 72 hours after birth of an Rho(D) positive infant, and to prevent isoimmunization in Rho(D) negative individuals who have been transfused with Rho(D) positive red blood cells or blood components containing red blood.
Contraindications	None known. Rho(D) Immune Globin (Human) should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immune globulin preparations
Viral Safety Process	Precipitation, depth filtration, solvent/detergent treatment. The final container incubation step used during the manufacture of HyperRho S/D contributes to virus inactivation.
Route of Administration	Intramuscular
Clearance of Rh-positive Red Blood Cells	Mini-Dose Each single dose syringe contains sufficient anti-Rho(D) to effectively suppress the immunizing potential of 2.5 mL of Rho(D) positive packed red blood cells or the equivalent of whole blood (5 mL). Full Dose Each single dose syringe contains sufficient anti-Rho(D) to effectively suppress the immunizing potential of 15 mL of Rho(D) positive red blood cells.
Product Half-Life	Approx. 23-26 days
Latex Content	HyperRhO S/D mini-dose and HyperRho S/D full dose prefilled disposable syringes in a latex-free delivery system.
Thimerosal Content	No
Storage Requirements/Shelf Life	Refrigerate at 2°C-8°C (36°F-46°F). Do not freeze. Do not use past expiration date listed on label.
Supply Method	Preservative (thimerosol)-free, prefilled disposable syringes with attached UltraSafe Needle Guard in a latex-free delivery system
Available Sizes	Mini-Dose: 250 IU prefilled disposable syringe in 10pk Full Dose: 1500 IU prefilled disposable syringe in 10pk and single syringe